Please assess the completion status of the following clinical trial:

Trial Title: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have a histologically confirmed NKTL at study site.~2. Subject must have relapsed or refractory NKTL after prior asparaginase-based chemotherapy or chemo radiotherapy.~3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.~4. Subject must have at least one evaluable or measurable lesion per Lugano 2014 classification.~5. Subject must have adequate organ function and bone marrow function without severe hematopoietic disorder, or heart, lung, liver or kidney dysfunction or immune deficiency.~6. Subject must provide stained tumor tissue sections and corresponding pathological report or unstained tumor tissue sections (or tissue block) for central pathology review.~7. Subject with prior anti-cancer treatment can only be enrolled when the toxicity of prior anti-cancer treatment has recovered to baseline or ≤ Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03.~Exclusion Criteria:~1. Invasive natural killer leukemia.~2. Concomitant with hemophagocytic syndrome.~3. Primary site in central nervous system (CNS) or CNS involvement.~4. Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS1001.~5. Subjects who received systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS1001.~6. Subjects who had prior chemotherapy, immune therapy, biological therapy as systemic treatment for cancer, within 28 days prior to the first dose of CS1001.~7. Receipt of traditional medicinal herbal preparations with anti-tumor indications with 7 days prior to the first dose of CS1001.~8. Known history of human immunodeficiency virus (HIV) infection and/or acquired immune deficiency syndrome.~9. Subjects with active hepatitis B or C infection.~10. Subjects with active tuberculosis infection.~11. Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA-4 monoclonal antibody.~12. Female subjects who are pregnant or breast-feeding.~For more information regarding trial participation, please contact at cstonera@cstonepharma.com

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CS1001 (Type: EXPERIMENTAL): Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).